Sanofi‘s (NYSE:SNY) long-acting insulin glargine, Toujeo, met the primary objective of a head-to-head trial comparing it to Novo Nordisk‘s (NYSE:NVO) insulin degludec, Tresiba, the company reported today.
The insulin-maker said it plans to report full results from the Bright trial sometime next year. The study’s primary objective was to determine if Toujeo had a similar effect on blood sugar levels compared to insulin degludec.
Secondary endpoints of the trial included the proportion of participants who experienced adverse events, the number of people with low blood sugar events and the rate of low blood sugar events.
Sanofi’s Bright trial enrolled 929 adults with Type II diabetes who had failed to control their blood sugar levels with non-insulin medications.
“The most recently introduced long-acting insulins have already demonstrated significant blood glucose lowering benefit to adult patients with diabetes. From the perspective of physicians and patients, hypoglycemia remains a major limiting factor in effective blood sugar management in diabetes. We believe that these first comparative clinical data assessing similarity and difference not only in efficacy, but also in the important safety aspect, such as low blood sugar events, can support physicians in their treatment decisions,” Riccardo Perfetti, head of Sanofi’s global diabetes medical team, said in prepared remarks. “We look forward to release of the full results of the study.”
